Castle Biosciences, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$20.70
FAIR PRICE
$39.14
MARGIN
$18.44
P/E Ratio
N/A
Div. Yield
N/A
ROE
-8.0%
Average
Market Cap
$628M
Small-cap
NOW AVAILABLE
Get notified when CSTL's fair price changes
Push notifications when CSTL's valuation shifts. Available on iOS and Android.
FPI RATING
Low debt levels and consistent growth trajectory, but weak profitability margins and below-average fundamental quality.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$31.31
Fair price × 0.80
DISTANCE
51.3%
Price to entry level
At the current price of $20.70, CSTL trades 51.3% below the conservative entry level of $31.31. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate CSTL's fair price
Castle Biosciences, Inc.'s fair price of $39.14 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $20.70, CSTL trades 89.1% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting CSTL's risk profile.
RELATIVE · 30%
Comparing CSTL's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for CSTL, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate CSTL's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for CSTL.
Explore on BuliosFAQ
What is the fair price of CSTL?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Castle Biosciences, Inc. is $39.14. At the current market price of $20.70, CSTL trades 89.1% below its calculated fair value.
Is CSTL overvalued or undervalued?+
Castle Biosciences, Inc. is currently undervalued based on our valuation model. The stock trades at $20.70, which is 89.1% below the fair price of $39.14.
What is the margin of safety for CSTL?+
With a 20% margin of safety applied to the fair price of $39.14, the conservative entry level for CSTL is $31.31. At the current market price of $20.70, the stock trades 51.3% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is CSTL's fair price updated?+
We update fair price calculations for CSTL daily after market close. The current fair price of $39.14 incorporates the latest market data and sector multiples.
What factors affect CSTL's fair price calculation?+
CSTL's fair price of $39.14 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -8.0%.
Is CSTL a good buy right now?+
At $20.70, CSTL trades 89.1% below our fair value estimate of $39.14. The stock is currently undervalued. ROE stands at -8.0% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does CSTL pay dividends?+
CSTL does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.